Date: 2017-09-12
Type of information: Nomination
Compound: clinical advisory board
Company: Lysogene (France)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nominatin
Action mechanism:
Disease:
Details:
- • On September 12, 2017, Lysogene announced the appointments of leading experts to its newly
formed clinical advisory board (CAB). The CAB will provide strategic advice to Lysogene as it continues to advance its clinical development programs and devise commercialization paths for its orphan gene therapy candidates to treat rare CNS diseases, beginning with mucopolysaccharidosis type IIIA (MPS IIIA) and GM1 gangliosidosis patients.
- Lysogene’s inaugural CAB members include:
- -Anupam Chakrapani, MD, Great Ormond Street Hospital for Children NHS (GOSH), London, UK
- -Ronald G. Crystal, MD, Weill Cornell Medicine, New York, USA
- -Roberto Giugliani, PhD, MSc, MD, University of Rio Grande do Sul, Porto Alegre, Brazil
- -Bénédicte Héron, MD, Armand-Trousseau Hospital, APHP, Paris, France
- -Nicole M. Muschol, MD, University Medical Center Hamburg-Eppendorf, Germany
- -Raymond Y. Wang, MD, Children's Hospital of Orange County, CA, USA
- -Chester B. Whitley, PhD, MD, University of Minnesota, MN, USA
- -Michel Zerah, MD, Necker Enfants Malades, Paris, France
Financial terms:
Latest news:
Is general: Yes
